Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Claggett

Showing results (291-300 of 362) with videos related to

Pageof 37
Sort By:
European Journal of Heart Failure|February 28, 2014
Sex-specific cardiovascular structure and function in heart failure with preserved ejection fractionMauro Gori, Carolyn S P Lam, Deepak K Gupta, et al.
European Journal of Heart Failure|June 9, 2025
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fractionRiccardo M Inciardi, Muthiah Vaduganathan, Brian Claggett, et al.
Circulation. Heart Failure|April 19, 2018
When the VEST Does Not Fit: Representations of Trial Results Deviating From Rigorous Data InterpretationLarry A Allen, Eric D Adler, Antoni Bayés-Genis, et al.
JACC. Heart Failure|October 13, 2023
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF TrialMaria Pabon, Jon Cunningham, Brian Claggett, et al.
Circulation|March 6, 2023
Risk of Incident Thromboembolic and Ischemic Events After COVID-19 Vaccination Compared With SARS-CoV-2 InfectionMats C Højbjerg Lassen, Daniel Modin, Kristoffer Grundtvig Skaarup, et al.
JACC. Heart Failure|April 28, 2022
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialMaja Cikes, Ivo Planinc, Brian Claggett, et al.
JACC. Heart Failure|July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF TrialMauro Gori, Michele Senni, Brian Claggett, et al.
European Journal of Heart Failure|March 27, 2020
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndromeSung-Hee Shin, Brian Claggett, Marc A Pfeffer, et al.
The American Journal of Gastroenterology|May 28, 2021
Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor TherapyJulia J Liu, Meredith E Sloan, Anna H Owings, et al.
Journal of the American College of Cardiology|September 1, 2024
Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 DiabetesBrendon L Neuen, John W Ostrominski, Brian Claggett, et al.
Pageof 37

Showing results (291-300 of 362) with videos related to

Sort By:
Pageof 37
European Journal of Heart Failure|February 28, 2014
Sex-specific cardiovascular structure and function in heart failure with preserved ejection fractionMauro Gori, Carolyn S P Lam, Deepak K Gupta, et al.
European Journal of Heart Failure|June 9, 2025
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fractionRiccardo M Inciardi, Muthiah Vaduganathan, Brian Claggett, et al.
Circulation. Heart Failure|April 19, 2018
When the VEST Does Not Fit: Representations of Trial Results Deviating From Rigorous Data InterpretationLarry A Allen, Eric D Adler, Antoni Bayés-Genis, et al.
JACC. Heart Failure|October 13, 2023
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF TrialMaria Pabon, Jon Cunningham, Brian Claggett, et al.
Circulation|March 6, 2023
Risk of Incident Thromboembolic and Ischemic Events After COVID-19 Vaccination Compared With SARS-CoV-2 InfectionMats C Højbjerg Lassen, Daniel Modin, Kristoffer Grundtvig Skaarup, et al.
JACC. Heart Failure|April 28, 2022
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialMaja Cikes, Ivo Planinc, Brian Claggett, et al.
JACC. Heart Failure|July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF TrialMauro Gori, Michele Senni, Brian Claggett, et al.
European Journal of Heart Failure|March 27, 2020
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndromeSung-Hee Shin, Brian Claggett, Marc A Pfeffer, et al.
The American Journal of Gastroenterology|May 28, 2021
Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor TherapyJulia J Liu, Meredith E Sloan, Anna H Owings, et al.
Journal of the American College of Cardiology|September 1, 2024
Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 DiabetesBrendon L Neuen, John W Ostrominski, Brian Claggett, et al.
Pageof 37